Skip to content
Clinical Trials – home

CEFUROXIME SODIUM: A Comprehensive Guide for Patients

2 / 3
trials open to patients / all trials
2+
Countries

In short

Cefuroxime Sodium is an antibiotic medication being studied in various clinical trials to evaluate its effectiveness in preventing and treating infections. These trials are examining different dosing strategies, administration methods, and patient populations to optimize the use of cefuroxime and improve patient outcomes. The research spans areas such as surgical prophylaxis, treatment of infections during pregnancy, and use in infants and children.

At a glance

Main Uses
Surgical prophylaxis, treatment of infections (e.g., pyelonephritis), antibiotic for infants and children
Administration Methods
Intravenous (IV), oral, bolus doses, continuous infusion
Patient Populations
Adults undergoing surgery, pregnant women, obese patients, newborns, infants, children
Key Study Areas
Dosing strategies, timing of administration, effectiveness in different patient groups, pharmacokinetics in special populations
Potential Benefits
Reduced post-surgical infections, effective treatment without hospitalization, appropriate dosing for various patient groups
Considerations
BMI-based dosing, effects on newborn gut microbiota, use in patients with altered physiology (e.g., post-cardiac surgery)

What is Cefuroxime?

Cefuroxime sodium is an antibiotic medication used to treat various bacterial infections. It belongs to a class of drugs called cephalosporins, which work by killing bacteria or preventing their growth. Cefuroxime is also known by other names, including: Ceftin Cefuroxime "Fresenius Kabi" These alternative names may be used in different countries or by different manufacturers.

Uses of Cefuroxime

Cefuroxime is prescribed to treat a variety of bacterial infections, including: Urinary tract infections (UTIs): Including those that occur during pregnancy Pyelonephritis: A serious kidney infection that can occur during pregnancy Surgical site infections: To prevent infections after various surgeries, including cesarean sections and colorectal surgeries Respiratory infections: Such as pneumonia in infants and children It's important to note that cefuroxime is effective against many types of bacteria, but it doesn't work for viral infections like the common cold or flu.

How Cefuroxime is Administered

Cefuroxime can be given in several ways, depending on the specific condition being treated and the patient's age: Intravenous (IV) injection: Directly into a vein, often used in hospital settings Oral tablets: Taken by mouth, usually for less severe infections or after initial IV treatment Continuous infusion: A method being studied where the drug is given continuously over a period of time The method of administration will be determined by your healthcare provider based on your specific condition and needs.

Dosage Information

The dosage of cefuroxime varies depending on several factors, including: The type and severity of the infection The patient's age and weight Kidney function Other medical conditions For example, in adults, common dosages range from 750 mg to 1.5 g given every 8 hours for intravenous administration. For oral administration, dosages may be around 500 mg every 12 hours. However, it's crucial to follow your doctor's specific instructions, as they will determine the right dosage for your individual case.

Effectiveness and Safety

Cefuroxime has been shown to be effective in treating various bacterial infections. Research is ongoing to determine its optimal use in different situations. For instance: Studies are comparing the effectiveness of oral versus intravenous cefuroxime in treating pyelonephritis during pregnancy Research is being conducted on the best timing of cefuroxime administration before surgery to prevent infections The safety and effectiveness of cefuroxime in newborns and infants are being studied These ongoing studies aim to improve our understanding of how to use cefuroxime most effectively and safely in different patient groups.

Potential Side Effects

Like all medications, cefuroxime can cause side effects, although not everyone experiences them. Common side effects may include: Nausea or vomiting Diarrhea Stomach pain Headache Skin rash In rare cases, more serious side effects can occur. It's important to inform your healthcare provider if you experience any unusual symptoms while taking cefuroxime.

Use in Special Populations

Cefuroxime is used in various patient groups, but special considerations may apply: Pregnant women: Cefuroxime is often used to treat infections during pregnancy, but the timing of administration for surgical prophylaxis is being studied Newborns and infants: Research is ongoing to determine the best dosages and safety profile in this age group Obese patients: Studies are looking at how to adjust dosages based on body mass index (BMI) Patients with kidney problems: Dosage adjustments may be necessary for patients with impaired kidney function Your healthcare provider will consider these factors when prescribing cefuroxime.

Ongoing Research

Several clinical trials are currently underway to further our understanding of cefuroxime: Comparing oral versus intravenous administration in pregnant women with kidney infections Studying the effects of cefuroxime on gut bacteria in newborns Investigating the best dosing strategies for preventing surgical site infections Examining how cefuroxime behaves in the bodies of infants after heart surgery These studies aim to improve the use of cefuroxime and enhance patient outcomes in various clinical scenarios.

Questions people often ask

Conditions where Cefuroxime Sodium is being studied

Each condition opens its own overview and trial list

Trials with Cefuroxime Sodium

Recruiting trials first

See all 3 →
Quick filters
  • Participants:All ages
  • Participants:Adults
  • Participants:Children
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).